PP14 Value-Based Pricing For Advanced Therapy Medicinal Products: Emerging Affordability Solutions

Introduction The emergence of advanced therapy medicinal products (ATMPs), a disruptive class health technologies, is generating important challenges in terms value assessment, and their high prices introduce critical access affordability concerns. Methods aim this oral presentation to expose the traditional assessment pricing reimbursement methods evaluation ATMPs, characterize current prospective financing solutions that may ensure patient for these technologies. Results Standard technology (HTA) not designed assessing ATMPs delay therapies; thus, broader concept required. As result, value-based methodologies have been gaining prominence as way cope with specific ATMPs. framework should balance between encouraging innovation maximizing money payers through attribution fair price new provision early scientific advice developers by regulatory HTA bodies key, it will help diminish perspective gap developers, regulators, payers. Conclusions efficacy dynamic many necessitates novel models, both European Union USA. Managed entry agreements, where conditional upon submission additional evidence, linked leased payments offer effective strategies address uncertainties caused evidence associated ensuring affordable sustained therapies.